Luc Lebeau

Dr. Luc Lebeau

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Dimitrios SkoufiasDimitrios Skoufias
Dimitrios Skoufias
SDSalvatore DeBonis
Salvatore DeBonis
YSYasmina Saoudi
Yasmina Saoudi
LLLuc Lebeau
Luc Lebeau
ICIsabelle Crevel
Isabelle Crevel
FKFrank Kozielski
Frank Kozielski
Human Eg5, responsible for the formation of the bipolar mitotic spindle, has been identified recently as one of the targets of S-trityl-L-cysteine, a potent tumor growth inhibitor in the NCI 60 tumor cell line screen. Here we show that in cell-based assays S-trityl-L-cysteine does not prevent cell cycle progression at the S or G(2) phases but inhibits both separation of the duplicated centrosomes and bipolar spindle formation, thereby blocking cells specifically in the M phase of the cell cycle with monoastral spindles. Following removal of S-trityl-L-cysteine, mitotically arrested cells exit mitosis normally. In vitro, S-trityl-L-cysteine targets the catalytic domain of Eg5 and inhibits Eg5 basal and microtubule-activated ATPase activity as well as mant-ADP release. S-trityl-L-cysteine is a tight binding inhibitor (estimation of K(i,app) <150 nm at 300 mm NaCl and 600 nm at 25 mm KCl). S-trityl-L-cysteine binds more tightly than monastrol because it has both an approximately 8-fold faster association rate and approximately 4-fold slower release rate (6.1 microM(-1) s(-1) and 3.6 s(-1) for S-trityl-L-cysteine versus 0.78 microM(-1) s(-1) and 15 s(-1) for monastrol). S-trityl-L-cysteine inhibits Eg5-driven microtubule sliding velocity in a reversible fashion with an IC(50) of 500 nm. The S and D-enantiomers of S-tritylcysteine are nearly equally potent, indicating that there is no significant stereospecificity. Among nine different human kinesins tested, S-trityl-L-cysteine is specific for Eg5. The results presented here together with the proven effect on human tumor cell line growth make S-trityl-L-cysteine a very attractive starting point for the development of more potent mitotic inhibitors.

1 September 2000 in Cell
Verified
Journal Article
Closed access
BGBenoît Gigant
Benoît Gigant
PCPatrick Curmi
Patrick Curmi
CMCarole Martin-Barbey
Carole Martin-Barbey
ECElodie Charbaut
Elodie Charbaut
SLSylvie Lachkar
Sylvie Lachkar
MKMarcel Knossow
Marcel Knossow

1 September 2004 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SDSalvatore DeBonis
Salvatore DeBonis
Dimitrios SkoufiasDimitrios Skoufias
Dimitrios Skoufias
LLLuc Lebeau
Luc Lebeau
RLRoman Lopez
Roman Lopez
GRGautier Robin
Gautier Robin
FKFrank Kozielski
Frank Kozielski
Human Eg5, a member of the kinesin superfamily, plays a key role in mitosis, as it is required for the formation of a bipolar spindle. We describe here the first in vitro microtubule-activated ATPase-based assay for the identification of small-molecule inhibitors of Eg5. We screened preselected libraries obtained from the National Cancer Institute and identified S-trityl-l-cysteine as the most effective Eg5 inhibitor with an IC50 of 1.0 μmol/L for the inhibition of basal ATPase activity and 140 nmol/L for the microtubule-activated ATPase activity. Subsequent cell-based assays revealed that S-trityl-l-cysteine induced mitotic arrest in HeLa cells (IC50, 700 nmol/L) with characteristic monoastral spindles. S-trityl-l-cysteine is 36 times more potent for inducing mitotic arrest than the well-studied inhibitor, monastrol. Gossypol, flexeril, and two phenothiazine analogues were also identified as Eg5 inhibitors, and we found that they all result in monoastral spindles in HeLa cells. It is notable that all the Eg5 inhibitors identified here have been shown previously to inhibit tumor cell line growth in the NCI 60 tumor cell line screen, and we conclude that their antitumor activity may at least in part be explained by their ability to inhibit Eg5 activity.

1 May 2015 in Biomaterials
Verified
Journal Article
Closed access
PPPhilippe Pierrat
Philippe Pierrat
RWRongrong Wang
Rongrong Wang
DKDimitri Kereselidze
Dimitri Kereselidze
MLMarie Lux
Marie Lux
PDPascal Didier
Pascal Didier
LLLuc Lebeau
Luc Lebeau

18 December 2002 in Biochemistry
Verified
Journal Article
Closed access
SDSalvatore DeBonis
Salvatore DeBonis
JSJean-Pierre Simorre
Jean-Pierre Simorre
ICIsabelle Crevel
Isabelle Crevel
LLLuc Lebeau
Luc Lebeau
Dimitrios SkoufiasDimitrios Skoufias
Dimitrios Skoufias
FKFrank Kozielski
Frank Kozielski

1 October 2007 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
EKEmmanuel Klein
Emmanuel Klein
SDSalvatore DeBonis
Salvatore DeBonis
BTBernd Thiede
Bernd Thiede
Dimitrios SkoufiasDimitrios Skoufias
Dimitrios Skoufias
FKFrank Kozielski
Frank Kozielski
LLLuc Lebeau
Luc Lebeau